In a 3‑month‑old infant with methicillin‑resistant Staphylococcus aureus (MRSA) ear discharge, is oral linezolid appropriate for a ten‑day course?

Oral Linezolid for 10 Days in a 3-Month-Old with MRSA Ear Discharge

Yes, oral linezolid is appropriate for a 10-day course in this 3-month-old infant with MRSA ear discharge, dosed at 10 mg/kg every 8 hours. This recommendation is supported by IDSA guidelines, FDA approval for infants, and specific evidence demonstrating effectiveness in pediatric MRSA otorrhea.

Dosing and Duration

For infants aged 3 months to <12 years, the correct linezolid dose is 10 mg/kg every 8 hours (not every 12 hours) 1, 2. This three-times-daily dosing is critical because:

• Linezolid clearance is most rapid in younger pediatric age groups (>1 week to 11 years)
• Every-8-hour dosing achieves similar daily AUC values as the every-12-hour adult regimen
• The 12-hour dosing interval is only appropriate for adolescents ≥12 years 2

Duration of 5-10 days is recommended for skin and soft tissue infections per IDSA guidelines 1, making your proposed 10-day course appropriate for MRSA ear discharge.

Evidence Supporting Use in Pediatric MRSA Otorrhea

The most directly relevant study demonstrates that oral linezolid at 20 mg/kg/day successfully treated all cases of refractory MRSA otorrhea in children, with complete resolution by day 14 3. In this series:

• 7 of 10 episodes were caused by MRSA
• All patients had failed conventional therapy including fluoroquinolone ear drops
• No adverse effects occurred
• The infection resolved without complications

Safety Profile in Infants

Linezolid is FDA-approved for use in infants and has demonstrated safety in this age group 2:

• Pharmacokinetic studies include infants >28 days to <3 months (N=12)
• Japanese experience showed 91% efficacy with only 13% adverse effects (primarily in teenagers, not infants) 4
• A review of 597 children treated with linezolid found it safe and effective 5
• Preliminary experience in PICU infants showed no complications with courses ranging from 7 days to 6 weeks 6

Key Advantages for This Clinical Scenario

Oral bioavailability is 100%, allowing equivalent efficacy to IV administration without need for vascular access 2. This is particularly valuable in a 3-month-old where:

• Prolonged IV access is difficult and risky
• Outpatient oral therapy enables discharge from hospital
• The drug can be administered without regard to meals 2

Important Caveats

1. Verify MRSA susceptibility to linezolid - though resistance is rare, confirmation is prudent

2. Monitor for thrombocytopenia if treatment extends beyond 2 weeks, though this is uncommon in short courses and more frequent in older patients 4, 7

3. Linezolid is expensive - reserve for documented MRSA or when conventional agents have failed 3

4. Do not use if Gram-negative coverage is needed - linezolid has no activity against Gram-negative organisms 2. If mixed infection is suspected, add appropriate Gram-negative coverage

5. Ensure adequate source control - while antibiotics are important, drainage of purulent material (if present) remains essential

Alternative Considerations

If linezolid is unavailable or cost-prohibitive, clindamycin 10-13 mg/kg/dose every 6-8 hours is an alternative if local MRSA clindamycin resistance rates are <10% and susceptibility is confirmed 1. However, given the specific evidence for linezolid in MRSA otorrhea 3, it represents the optimal choice when conventional therapy has failed.

The combination of IDSA guideline support 1, FDA approval for this age group 2, and specific evidence of effectiveness in pediatric MRSA ear infections 3 makes oral linezolid an evidence-based choice for this clinical scenario.